Meniere's Disease
Clinical guidelines for managing fluctuating endolymphatic pressure, dietary sodium restriction, and intratympanic rescue therapies.
Table of Contents
π§ Standard of Care & Symptoms
Meniere's Disease is a chronic disorder of the inner ear that affects both balance and hearing, typically presenting in one ear but potentially becoming bilateral over time.
- The Symptom Tetrad:
- Episodic Vertigo: Spontaneous, severe spinning sensations lasting from 20 minutes to several hours, often accompanied by nausea and vomiting.
- Sensorineural Hearing Loss: Fluctuating loss, typically affecting lower frequencies initially, which can become permanent and progressive.
- Tinnitus: Low-pitched ringing, roaring, or buzzing in the affected ear.
- Aural Fullness: A sensation of pressure or congestion in the ear.
- Pathophysiology: Associated with **endolymphatic hydrops**, an abnormal accumulation of endolymph fluid within the membranous labyrinth of the inner ear, disrupting signals to the brain.
π₯ Dietary & Lifestyle Changes
Conservative dietary modifications serve as the primary long-term management strategy to reduce fluid pressure fluctuations in the inner ear.
- Low-Sodium Diet: Restricting sodium intake to **1,500 mg to 2,000 mg** per day. Crucially, sodium intake must be distributed evenly across all meals to prevent sudden shifts in body fluid osmolarity.
- Limiting Fluid Triggers: Reducing intake of caffeine, alcohol, and high-sugar foods, which can affect inner ear electrolyte balances.
- Vestibular Rehabilitation Therapy (VRT): A specialized exercise program to train the brain to cope with abnormal balance signals from the affected ear, particularly helpful between vertigo attacks.
π Medications & Intratympanic Injections
Medical management targets both acute attacks and the prevention of future fluid buildup.
Acute Attack Relief
- Vestibular Suppressants: Medications like Meclizine or Diazepam, along with antiemetics (like Promethazine), are used short-term to suppress vertigo and control nausea.
Maintenance & Injections
- Diuretics: Oral diuretics (e.g. Triamterene/Hydrochlorothiazide) are widely prescribed to help the body shed excess fluid, reducing inner ear endolymph pressure.
- Intratympanic Steroids: Injections of Dexamethasone through the eardrum into the middle ear space can significantly reduce vertigo frequency while sparing the patient from systemic steroid side effects.
- Intratympanic Gentamicin: An aminoglycoside antibiotic injected to selectively destroy vestibular cells in severe, intractable cases. Gentamicin is vestibulotoxic, posing a risk of permanent hearing loss, and is reserved as a late-stage option.
π Diagnostic Testing & Assessment
Diagnosing Meniere's disease requires ruling out central neurological causes (such as vestibular Migraine or Acoustic Neuroma) and confirming inner ear fluid pressure abnormalities through specialized tests:
- Electrocochleography (ECochG): An electrophysiological test that measures the electrical potentials generated in the inner ear in response to sound. An elevated summating potential to action potential (SP/AP) ratio (> 0.35) is indicative of endolymphatic hydrops.
- Vestibular Evoked Myogenic Potentials (VEMP): Evaluates the function of the otolith organs (saccule and utricle) and the vestibular nerve pathways. It helps determine if there is damage to the balance organs and can track changes over time.
- Glycerol Dehydration Test: Involves administering oral glycerol (a dehydrating agent) followed by serial audiograms. A temporary improvement in hearing thresholds after ingestion suggests that reversible endolymphatic pressure was reduced.
π¬ Active Clinical Trials
Clinical trials are currently evaluating sustained-release middle ear implants, novel systemic neuroprotective agents, and gene therapies to regenerate inner ear hair cells.
A Phase III trial evaluating a novel sustained-release formulation of intratympanic dexamethasone gel for episodic vertigo control.
Key Inclusion: Age 18 to 75, diagnosed with unilateral definite Meniere's disease (AAO-HNS criteria), and experiencing at least 2 definitive vertigo episodes in the past 2 months.Testing a neuroprotective small-molecule antagonist designed to prevent glutamate-induced excitotoxicity in inner ear nerve terminals.
Key Inclusion: Definite unilateral Meniere's, duration of disease < 5 years (to ensure salvageable nerve fibers), and documented hearing fluctuation.Evaluating a non-invasive, localized pressure pulse delivery device for home management of acute attacks.
Key Inclusion: Patients with active episodic vertigo attacks, having a patent tympanostomy tube (grommet) in the affected ear, and capable of operating the portable pulse generator.πΊοΈ Next Steps After Diagnosis
If you have recently been diagnosed with Meniere's Disease, take these immediate steps:
- Establish a Sodium Tracking Diary: Record your daily sodium intake to ensure a flat, stable consumption profile throughout the day.
- Create a Vertigo Action Plan: Keep rescue medications (like meclizine) on hand. Sit or lie down immediately at the first sign of an attack to prevent falls.
- Schedule Baseline Audiology Exams: Work with an audiologist to document your hearing thresholds, which helps track disease progression.
- Discuss Intratympanic steroid options: If oral diuretics fail to control attacks, ask your ENT specialist about middle ear injections.
β Patient FAQ
Q: What is a "drop attack"?
A: In advanced Meniere's, some patients experience sudden, severe falls without loss of consciousness, known as Tumarkin's otolithic crises. They are caused by a sudden mechanical deformation of the otolith organs in the inner ear.
Q: Will Meniere's disease eventually affect both ears?
A: In the majority of patients, Meniere's remains unilateral (confined to one ear). However, studies show that 15% to 50% of patients may eventually experience symptoms in both ears after 10 to 20 years of disease history.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.